We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Organon & Co (OGN) USD0.01

Sell:$15.50 Buy:$15.70 Change: $0.03 (0.19%)
Market closed |  Prices as at close on 13 November 2024 | Switch to live prices |
Ex-dividend
Sell:$15.50
Buy:$15.70
Change: $0.03 (0.19%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 13 November 2024 | Switch to live prices |
Ex-dividend
Sell:$15.50
Buy:$15.70
Change: $0.03 (0.19%)
Market closed |  Prices as at close on 13 November 2024 | Switch to live prices |
Ex-dividend
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.

Contact details

Address:
30 Hudson Street, Fl 33
JERSEY CITY
07302
United States
Telephone:
+1 (551) 4306000
Website:
https://www.organon.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OGN
ISIN:
US68622V1061
Market cap:
$4.14 billion
Shares in issue:
257.54 million
Sector:
Pharmaceuticals
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Kevin Ali
    Chief Executive Officer, Director
  • Matthew Walsh
    Chief Financial Officer, Executive Vice President
  • Aaron Falcione
    Chief Human Resource Officer, Executive Vice President
  • Rachel Stahler
    Executive Vice President, Chief Information Officer
  • Kirke Weaver
    Executive Vice President, General Counsel, Corporate Secretary
  • Juan Ferreira
    Executive Vice President, Head of Research and Development and Chief Medical Officer
  • Susanne Fiedler
    Executive Vice President, Chief Commercial Officer
  • Joseph Morrissey
    Executive Vice President, Head of Manufacturing and Supply
  • Vittorio Nisita
    Executive Vice President, Head of Global Business Services

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.